Project 4 has been a leader in revealing the myriad roles played by microRNAs in human cancer. We will build upon this foundation with an increased biological focus on breast cancer. We will isolate the six, well defined mammary epithelial cell types from normal virgin and parous female mice and define their miRNA and mRNA expression profiles. In so doing, we hope to better define the mammary stem cell (MaSC) and gain an appreciation for the pathways that maintain its self-renewal. This will include a definition of miRNAs and miRNA targets that are important in the MaSC. Using normal cells as a reference point, we will work to understand the relationship between mammary tumor initiating cells and normal mammary stem cells. In part, we aim to test the relevance of tumor initiating populations, which thus far have only been detected in transplantation studies, to breast cancer in in vivo models of basal tumorigenesis. We hope to identify pathways that determine tumor initiating potential and to relate these to self-renewal pathways used by mammary stem cells. We appreciate that both normal and tumor cells function in context, and we will therefore strive to understand how the in vivo niche supports MaSC self-renewal. Similarly, we will ask whether tumor initiating cells occupy a niche or whether their special status is a cell autonomous property. With the realization that it is usually metastatic disease that kills patients, we will also probe the niches occupied by disseminated tumor cells, which can lie dormant for decades following initial treatment before they progress to frank metastases. Using a series of highly innovative strategies, including molecular profiling, RNAi-based genetics, and sophisticated imaging a whole, this Project takes a comprehensive approach to understanding the roles of miRNAs in breast cancer.
; One in every 8 women will be diagnosed with breast cancer in her lifetime. Despite substantial progress in molecular phenotyping and targeted therapy, we still lack the capacity to manage disease in the long term for more than 75% of women. The work proposed herein will deepen our understanding of breast cancer and may reveal new strategies for targeted intervention, particularly in the prevention of metastatic disease.
|Chakraborty, A A; Scuoppo, C; Dey, S et al. (2015) A common functional consequence of tumor-derived mutations within c-MYC. Oncogene 34:2406-9|
|Mazurek, Anthony; Park, Youngkyu; Miething, Cornelius et al. (2014) Acquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase DDX5. Cell Rep 7:1887-99|
|Huang, Chun-Hao; Lujambio, Amaia; Zuber, Johannes et al. (2014) CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev 28:1800-14|
|Saborowski, Michael; Saborowski, Anna; Morris 4th, John P et al. (2014) A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev 28:85-97|
|Fellmann, Christof; Lowe, Scott W (2014) Stable RNA interference rules for silencing. Nat Cell Biol 16:10-8|
|Jensen, Mads A; Wilkinson, John E; Krainer, Adrian R (2014) Splicing factor SRSF6 promotes hyperplasia of sensitized skin. Nat Struct Mol Biol 21:189-97|
|Weissmueller, Susann; Manchado, Eusebio; Saborowski, Michael et al. (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor ? signaling. Cell 157:382-94|
|Bolden, Jessica E; Tasdemir, Nilgun; Dow, Lukas E et al. (2014) Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition. Cell Rep 8:1919-29|
|Chen, Chong; Liu, Yu; Rappaport, Amy R et al. (2014) MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25:652-65|
|Das, Shipra; Krainer, Adrian R (2014) Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer. Mol Cancer Res 12:1195-204|
Showing the most recent 10 out of 509 publications